Hartford Investment Management Co. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,292 shares of the biopharmaceutical company’s stock after selling 10,607 shares during the period. Hartford Investment Management Co.’s holdings in Gilead Sciences were worth $21,042,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in GILD. Hall Laurie J Trustee boosted its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. boosted its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Finally, Webster Bank N. A. boosted its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Hedge funds and other institutional investors own 74.04% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.05% during trading on Friday, hitting $83.75. The stock had a trading volume of 14,311,629 shares. The stock’s 50-day moving average is $74.38 and its 200-day moving average is $69.29. The stock has a market cap of $109.37 billion, a price-to-earnings ratio of 9.10 and a beta of 1.18. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $84.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the company posted $3.08 earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.73 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Sold by Hartford Investment Management Co.” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-sold-by-hartford-investment-management-co/1538469.html.

Several analysts recently issued reports on the company. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Thursday. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price for the company. in a research report on Monday, August 28th. Cowen and Company reiterated an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research report on Wednesday, July 5th. Finally, Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Twelve equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $82.26.

In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last three months, insiders have sold 256,666 shares of company stock worth $19,173,184. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.